Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

Shares of Hims & Hers have surged 121.7% year to date compared with the industry’s gain of 22.9%. Image Source: Zacks Investment Research HIMS’ forward 12-month P/S of 4.7X is lower than the ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, following the announcement of a 4% reduction in its workforce.

Image Source: Zacks Investment Research Meanwhile, HIMS is trading at a forward 12-month price-to-sales (P/S) ratio of 4.6X, above its median of 2.3X over the past three years.

Shares of Hims & Hers soared $4.21, or 29%, to $18.79 in Monday afternoon trading. GLP-1 drugs, which stands for glucagon-like peptide 1 agonists, help people feel fuller and less hungry, aiding ...

Hims & Hers Health reported first-quarter earnings on Monday after the market closed and rocketed 18% after revenue more than doubled, and it raised full-year guidance.. Revenue hit $586 million ...

Shares of Hims & Hers and LifeMD both skyrocketed Tuesday following the news. Hims & Hers' stock jumped 30% in premarket trading and stayed at 23% by market close. Shares of LifeMD jumped 40% Tuesday.

Shares of Hims & Hers Health (HIMS 6.81%) and LifeMD (LFMD 1.55%) are surging on Tuesday. The companie' stocks had jumped 24% and 34%, respectively, as of 3:15 p.m. ET as the S&P 500 and the ...

The bundle will offer Novo Nordisk’s popular weight-loss drug at all its dosage strengths paired with a Hims & Hers membership providing "access to 24/7 care, ongoing clinical support, and ...

Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more acc ...